about
Acetate causes alcohol hangover headache in ratsOccipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility studyChronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trialAcetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled studyAcute migraine treatment: patterns of use and satisfaction in a clinical populationHemicrania continua responds to cyclooxygenase-2 inhibitorsTargeting sleep disruption using sodium oxybate in chronic cluster headache prophylaxisDHE in the pharmacotherapy of migraine: potential for a larger roleSpontaneous trigeminal allodynia in rats: a model of primary headache.Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data.Cardiovascular tolerability and safety of triptans: a review of clinical data.Headaches in pregnancy.Episodic migraine associated with postural orthostatic tachycardia syndrome and vasovagal syncope: migraine triggers neuromediated syncope.Diagnostic criteria for headache due to spontaneous intracranial hypotension: a perspective.Procedures for administering botulinum toxin type A for migraine and tension-type headache.Recent developments in migraine.Defining the pharmacologically intractable headache for clinical trials and clinical practice.Chronic migraine--classification, characteristics and treatment.Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study.OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.Neuroleptics in headache.A new frontier for headache.Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study.Use of common migraine treatments in breast-feeding women: a summary of recommendations.Drug overuse and rebound headache.Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial.Efficacy and Tolerability of STOPAIN for a Migraine AttackThe evolving management of migraine.Neurotoxins in the neurobiology of pain.MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.Late-life migraine accompaniments: A narrative review.The prevalence of migraine in neurologists.Botulinum toxin and other new approaches to migraine therapy.Headaches due to nasal and paranasal sinus disease.Inpatient treatment of headache: an evidence-based assessment.Anticonvulsants in migraine.Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.
P50
Q21091071-0CEEEA6E-F914-4514-AEE3-BD659CA1A379Q24598887-631532DA-A74C-41A7-8BEF-74C24E5B2066Q27347591-4E936ADE-1DFB-4F2F-A142-BD1DD58EA26EQ28188328-7B335CB2-ED9B-48AA-A272-B26BB16ECAB2Q28196594-85E577C9-1341-40F1-9C28-B81045B34A06Q28196819-228F9F5E-0578-4740-85B7-E710B6B89820Q28217118-6C7CA292-65AD-4113-9E16-13FB1B587BADQ28238563-16E046C7-BA4D-432D-80FB-AA05EA5DA7C3Q28271614-43B0A2AE-3121-449C-95B2-4520B7F52383Q30438339-AE4C9615-FE71-4176-B43D-4972E8661D1DQ30740922-01A63780-74F5-4A78-844C-4D7C98AEB18DQ30932202-DD6B3749-BA76-406C-982E-803376ADB927Q30968982-98A70A51-7F4D-4E57-966E-AC9CB8FBFD43Q33156162-3A8429C2-31A6-48BE-B077-AF1B599B121DQ33928013-3848939E-BBDB-438B-8F40-117F4620CCFBQ33967971-6FF99B90-C53E-4B70-835A-07EA3F9435DCQ34014252-4C7F08AA-C24B-4313-ABE6-A45D6C84FFC6Q34024368-C2D8A2F6-0DC3-41F2-AC91-AA2083AA2B92Q34030691-989F7FFB-7DCD-4B43-9178-11C1ACCAA09EQ34033827-5D1E4029-C255-4180-84F3-8269831D3027Q34116531-D7574D94-57B8-4A54-B323-FF750A286B60Q34173953-0F5E9C5A-407D-437F-946F-2CAB42E19401Q34412065-C60BC695-D5C5-4C33-A3A2-C77F4DAEECFEQ34436636-59C66866-2FE6-45B9-9BEA-7B381F63DA10Q34442510-D6B1FD93-EA02-45D0-80F1-09102A5ABCA6Q34597128-01E23B78-B064-47AE-9598-1F7CFF5466E7Q34610187-DAF70D14-74C0-4880-9CF8-B089FE5A4F48Q34633310-5F027ACC-B536-4B77-AC0F-906FE958C867Q34651329-B7351DDF-280C-4ABE-9C9D-564643930DD9Q35047835-D152F0C3-FAF0-4064-BACA-C016CE7E3B34Q35176506-377E2F42-3445-469F-96BE-DD6E2C14F11DQ35187497-158AB360-1E31-4A84-B4A8-25257E559AFCQ35248055-E38C9343-A79F-4031-BE02-FD8E90DEA71EQ35518633-C3286B28-B4AF-4079-9479-93A7B45B0110Q35580827-7E52F04E-24D7-4BB1-801F-B9220FFD354DQ35640305-249D476D-B812-4B39-A439-289E1B5B30ACQ35736690-CB225DB5-0977-4B8A-A13D-263C39DB34CAQ35756332-2308929D-1CC0-4A3D-9C24-D7E99C0E6C5FQ35759350-EF49914F-8583-43C0-9507-3FBB8784830FQ35775292-405F0016-0EBC-4206-B337-E1257C963E28
P50
description
researcher
@en
name
Stephen D. Silberstein
@en
Stephen D. Silberstein
@nl
type
label
Stephen D. Silberstein
@en
Stephen D. Silberstein
@nl
altLabel
S D Silberstein
@en
S Silberstein
@en
S. D. Silberstein
@en
S. Silberstein
@en
Silberstein S
@en
Silberstein S. D.
@en
Silberstein S.
@en
Silberstein SD
@en
Silberstein
@en
Stephen D Silberstein
@en
prefLabel
Stephen D. Silberstein
@en
Stephen D. Silberstein
@nl